0 Bewertungen
ID

26387

Beschreibung

Study Part: Pre-dose Checklist Week 1 PK Visit (Visit 3). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Stichworte

Versionen (1)
  1. 16.10.17 16.10.17 -
Rechteinhaber

GlaxoSmithKline

Hochgeladen am

16. Oktober 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

  • Neueste
  • Älteste
  • Beliebt
  • Neueste
    • Neueste
    • Älteste
    • Beliebt

    Keine Kommentare

    Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

    Pre-dose Checklist Week 1 PK Visit (Visit 3) Ropinirole Parkinson Disease 101468/165

    Englisch

    Pre-dose Checklist Week 1 PK Visit (Visit 3)

    1 Formulare  
    PREDOSE CHECKLIST
    Beschreibung

    PREDOSE CHECKLIST

    Alias
    UMLS CUI-1
    C0439565
    UMLS CUI-2
    C1707357
    Patient Number
    Beschreibung

    Patient Number

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C1830427
    Centre Number
    Beschreibung

    Centre Number

    Datentyp

    integer

    Alias
    UMLS CUI [1,1]
    C0600091
    UMLS CUI [1,2]
    C0019994
    Visit Date
    Beschreibung

    Visit Date

    Datentyp

    date

    Alias
    UMLS CUI [1]
    C1320303
    1. Has the patient refrained from consuming alcohol for 24 hours prior to the clinic visit?
    Beschreibung

    alcohol consumption

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0001948
    2. Has the patient tried to refrain from consuming xanthine-containing beverage and foods (coffee, tea, cola beverages, cocoa, chocolate), grapefruit-containing products, quinine-containing products and food containing CYP1A2-inducing constituents (broccoli, bussels sprouts, cabbage etc.) within 24 hours of the clinic visit?
    Beschreibung

    xanthine-containing beverage and foods

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0043314
    UMLS CUI [1,2]
    C0016452
    3. Has the patient refrained from consuming poppy seed-containing food (e.g. poppy cake) for three days before the clinic visit?
    Beschreibung

    poppy seed-containing food

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0453264
    UMLS CUI [1,2]
    C0016452
    4. Has the patient maintained their normal smoking practice?
    Beschreibung

    smoking history

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C1519384
    5. Has the subject had at least 3 sequential days of dosing?
    Beschreibung

    dosage

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C0178602
    6. If the patient is already taking a drug known to substantially inhibit CYP1A2 or induce CYP1A2, has the patient remained on stable doses of the agent from 7 days prior to dosing with study medication?
    Beschreibung

    CYP1A2 inhibitors or inducers

    Datentyp

    text

    Alias
    UMLS CUI [1,1]
    C1827504
    UMLS CUI [1,2]
    C1827490
    Comments:
    Beschreibung

    Comments

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C0947611
    Zum Seitenanfang zurückkehren

    Ähnliche Modelle

    Pre-dose Checklist Week 1 PK Visit (Visit 3)

    1 Formulare
    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datentyp
    Alias
    Item Group
    PREDOSE CHECKLIST
    C0439565 (UMLS CUI-1)
    C1707357 (UMLS CUI-2)
    Patient Number
    Item
    Patient Number
    text
    C1830427 (UMLS CUI [1])
    Centre Number
    Item
    Centre Number
    integer
    C0600091 (UMLS CUI [1,1])
    C0019994 (UMLS CUI [1,2])
    Visit Date
    Item
    Visit Date
    date
    C1320303 (UMLS CUI [1])
    alcohol consumption
    Item
    1. Has the patient refrained from consuming alcohol for 24 hours prior to the clinic visit?
    boolean
    C0001948 (UMLS CUI [1])
    xanthine-containing beverage and foods
    Item
    2. Has the patient tried to refrain from consuming xanthine-containing beverage and foods (coffee, tea, cola beverages, cocoa, chocolate), grapefruit-containing products, quinine-containing products and food containing CYP1A2-inducing constituents (broccoli, bussels sprouts, cabbage etc.) within 24 hours of the clinic visit?
    boolean
    C0043314 (UMLS CUI [1,1])
    C0016452 (UMLS CUI [1,2])
    poppy seed-containing food
    Item
    3. Has the patient refrained from consuming poppy seed-containing food (e.g. poppy cake) for three days before the clinic visit?
    boolean
    C0453264 (UMLS CUI [1,1])
    C0016452 (UMLS CUI [1,2])
    Item
    4. Has the patient maintained their normal smoking practice?
    text
    C1519384 (UMLS CUI [1])
    smoking history
    Code List
    4. Has the patient maintained their normal smoking practice?
    CL Item
    Yes (Yes)
    CL Item
    No (No)
    CL Item
    N/A (N/A)
    Item
    5. Has the subject had at least 3 sequential days of dosing?
    text
    C0178602 (UMLS CUI [1])
    smoking history
    Code List
    5. Has the subject had at least 3 sequential days of dosing?
    CL Item
    Yes (Yes)
    CL Item
    No (No)
    CL Item
    N/A (N/A)
    Item
    6. If the patient is already taking a drug known to substantially inhibit CYP1A2 or induce CYP1A2, has the patient remained on stable doses of the agent from 7 days prior to dosing with study medication?
    text
    C1827504 (UMLS CUI [1,1])
    C1827490 (UMLS CUI [1,2])
    smoking history
    Code List
    6. If the patient is already taking a drug known to substantially inhibit CYP1A2 or induce CYP1A2, has the patient remained on stable doses of the agent from 7 days prior to dosing with study medication?
    CL Item
    Yes (Yes)
    CL Item
    No (No)
    CL Item
    N/A (N/A)
    Comments
    Item
    Comments:
    text
    C0947611 (UMLS CUI [1])
    Zum Seitenanfang zurückkehren 

    Hilfe

    Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

    Zum Video